FDA, Cancer, Multiple Myeloma discussed on Tennessee Matters


Is is always encouraged and leads to. Leads to successes and new new treatments being developed. I think more work needs to be done on the reimbursement side, especially with these new therapies like I've just described. I am not an expert in public policy or government relations for healthcare. But I do know that we with these new gene therapies like car cell therapy. We need to figure out a way to. To fun sustainably the treatment of Medicare patients in particular who need these therapies. When we are looking ahead at some of the trials that are going on understand that there are a lot of moving parts. And and you you don't necessarily have a timetable on when things are going to get done. I have there been any specific breakthroughs, or at least maybe some positive signs on on any of those particular fronts with regard to treatments that maybe they at least signs of treatments that are coming that. Maybe he didn't have much hope for maybe six months ago or a year ago. Absolutely within each of those categories of blood cancers, we've had successes come along. I mentioned car tesol therapy. That's been FDA approved within the last year. And that's offer treatment hope for people who really were without hope in leukemia in particular, acute myeloid leukemia. There's been several new FDA approved medications to treat AM L or acute myeloid leukemia within the last several months, and in fact prior there hadn't been FDA approved therapies for refractory and Allen in decades. So there's certainly making progress in in the fight against multiple myeloma fifteen twenty years ago, it was a grim prognosis. And we now have a number of different categories of treatments for multiple myeloma patients that have have come along within the last ten years or Carlo bit longer and that we're. Continuing to refine and survivals improved for all these categories. Blood cancer within the last ten years. So there are some positive there's some positive steps in some some noted progress that's being made yet from the information. I understand that your team sent me that I guess less than five percent of adults living with cancer will enroll in a cancer clinical trial. Why is that? Well, not every cancer physician or cancer center will offer clinical trials or they may not offer clinical trial specific to the type of cancer that that patient has. But I think it's truly important that that cancer patients and their families are aware of clinical trials this offer what he's are offering treatments that doctors and scientists believe could be better than what currently exists and all those new treatments that I've mentioned are because people were willing to engage in clinical trials, try new things out. And so I always encourage people to seek out what clinical trials there could be eligible for. And and I think you know, we need to encourage people to get second. Opinions. There's a lot that we've covered here. And certainly the new at imagine that part of our audience has a need to find out more for themselves. We're gonna go online to do that. So patients and their families can go to the lukaemia lymphoma society at L L, S dot org. On that website. They can also find a phone number for a patient helpline or they can get help. Navigating patients to open clinical trials. In addition. I always encourage people to go to clinical trials dot gov. That is a website maintained by the federal government where patients and their families can search for clinical trials said that are open for their particular.

Coming up next